Abstract
Currently, no general methods have been developed to relate pharmacologically based models, such as indirect response models, to discrete or ordered categorical data. We propose the use of an unobservable latent variable (LV), through which indirect response models can be linked with drug exposure. The resulting indirect latent variable response model (ILVRM) is demonstrated using a case study of a JAK3 inhibitor, which was administered to patients in a rheumatoid arthritis (RA) study. The clinical endpoint for signs and symptoms in RA is the American College of Rheumatology response criterion of 20%—a binary response variable. In this case study, four exposure-response models, which have different pharmacological interpretations, were constructed and fitted using the ILVRM method. Specifically, two indirect response models, an effect compartment model, and a model which assumes instantaneous (direct) drug action were assessed and compared for their ability to predict the response data. In general, different model interpretations can influence drug inference, such as time to drug effect onset, as well as affect extrapolations of responses to untested experimental conditions, and the underlying pharmacology that operates to generate key response features does not change because the response was measured discretely. Consideration of these model interpretations can impact future study designs and ultimately provide greater insight into drug development strategies.
Similar content being viewed by others
References
Dayneka NL, Garg V and Jusko WJ (1993). Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokin Biopharm 21: 457–478
Sheiner LB, Beal SL and Dunne A (1997). Analysis of nonrandomly censored ordered categorical longitudinal data from analgesic trials. JASA 92: 1235–1255
Lee H, Kimko HC, Rogge M, Wang D, Nestorov I and Peck CC (2003). Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis. Clin Pharmacol Ther 73: 348–365
Hutmacher MM, Nestorov I, Ludden T, Zitnik R and Banfield C (2007). Modeling the exposure-response relationship of etanercept in the treatment of patients with chronic moderate to severe plaque psoriasis. J Clin Pharmacol 47: 238–248
Johnston JA, Bacon CM, Riedy MC and O’Shea JJ (1996). Signaling by IL-2 and related cytokines: JAKs, STATs, and relationship to immunodeficiency. J Leukoc Biol 60: 441–452
Changelian PS, Flanagan ME, Ball DJ, Kent CR, Magnuson KS, Martin WH, Rizzuti BJ, Sawyer PS, Perry BD, Brissette WH, McCurdy SP, Kudlacz EM, Conklyn MJ, Elliott EA, Koslov ER, Fisher MB, Strelevitz TJ, Yoon K, Whipple DA, Sun J, Munchhof MJ, Doty JL, Casavant JM, Blumenkopf TA, Hines M, Brown MF, Lillie BM, Subramanyam C, Shang-Poa C, Milici AJ, Beckius GE, Moyer JD, Su C, Woodworth TG, Gaweco AS, Beals CR, Littman BH, Fisher DA, Smith JF, Zagouras P, Magna HA, Saltarelli MJ, Johnson KS, Nelms LF, Des Etages SG, Hayes LS, Kawabata TT, Finco-Kent D, Baker DL, Larson M, Si MS, Paniagua R, Higgins J, Holm B, Reitz B, Zhou YJ, Morris RE, O’Shea JJ and Borie DC (2003). Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302: 875–878
Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, Katz LM, Paulus H, Strand V, Tugwell P, Weinblatt M, Williams HJ, Wolfe F, Kieszak S and Lightfoot R Jr (1995). ACR preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38: 727–735
Kremer JM, Bloom BJ, Breedveld FC, Coombs J, Fletcher MP, Gruben D, Krishnaswami S, Burgos R-Vargas, Wilkinson B, Zerbini CAF and Zwillich SH (2006). A randomized, double-blind, placebo-controlled trial of 3 dose levels of CP-690,550 versus placebo in the treatment of active rheumatoid arthritis. Arthritis Rheum 54: 4116
Sharma A and Jusko WJ (1996). Characterization of four basic models of indirect pharmacodynamic responses. J Pharmacokin Biopharm 24: 611–635
Beal SL and Sheiner LB (1989–1998). NONMEM users guides. Globomax Inc, Maryland
Kowalski KG, McFadyen L, Hutmacher MM, Frame B and Miller R (2003). A two-part mixture model for longitudinal adverse event severity data. J Pharmacokin Pharmacodynam 30: 315–336
Liu J, Kowalski KG, Bockbrader HN, Burger PJ, Corrigan BW, Hermann D, Frame B, Lalonde LR, Miller R (2003) Two-step population analysis of pregabalin exposure-adverse event severity in patients with neuropathic pain, generalized anxiety disorder, or partial seizures. AAPS Annual Meeting. Salt Lake City, Utah, USA, October, pp 26–30
Gibbons RD and Hedeker D (1997). Random effects probit and logistic regression models for three-level data. Biometrics 53: 1527–1537
McCullagh P (1980). Regression models for ordinal data. Statist J R Soc B 42: 109–142
Weyand CM and Goronzy JJ (1997). Pathogenesis of rheumatoid arthritis. Med Clin North Am 81: 29–55
(1964). Handbook of mathematical functions. National Bureau of Standards, Washington DC, 932
Hutmacher MM, Mukherjee D, Kowalski KG and Jordan DC (2005). Collapsing mechanistic models: an application to dose selection for proof of concept of a selective irreversible antagonist. J Pharmacokin Pharmacodynam 32: 501–520
Sheiner LB, Stanski DR, Vozeh S, Miller RD and Ham J (1979). Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to D-turbocurarine. Clin Pharmacol Ther 25: 358–371
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hutmacher, M.M., Krishnaswami, S. & Kowalski, K.G. Exposure-response modeling using latent variables for the efficacy of a JAK3 inhibitor administered to rheumatoid arthritis patients. J Pharmacokinet Pharmacodyn 35, 139–157 (2008). https://doi.org/10.1007/s10928-007-9080-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10928-007-9080-2